During The Past Six Months, Hepion Pharmaceuticals Inc (NASDAQ: HEPA) Shares Took An -36.30% Jump. Here Is What We Should Expect

During the last session, Hepion Pharmaceuticals Inc (NASDAQ:HEPA)’s traded shares were 0.47 million, with the beta value of the company hitting 1.69. At the end of the trading day, the stock’s price was $0.64, reflecting an intraday gain of 28.79% or $0.15. The 52-week high for the HEPA share is $3.49, that puts it down -445.31 from that peak though still a striking 32.81% gain since the share price plummeted to a 52-week low of $0.43. The company’s market capitalization is $4.43M, and the average intraday trading volume over the past 10 days was 46190.0 shares, and the average trade volume was 48.26K shares over the past three months.

Hepion Pharmaceuticals Inc (HEPA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. HEPA has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.

Hepion Pharmaceuticals Inc (NASDAQ:HEPA) trade information

Hepion Pharmaceuticals Inc (HEPA) registered a 28.79% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 28.79% in intraday trading to $0.64, hitting a weekly high. The stock’s 5-day price performance is 28.69%, and it has moved by 5.41% in 30 days. Based on these gigs, the overall price performance for the year is -78.77%. The short interest in Hepion Pharmaceuticals Inc (NASDAQ:HEPA) is 65726.0 shares and it means that shorts have 0.92 day(s) to cover.

The consensus price target of analysts on Wall Street is $70, which implies an increase of 99.09% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $70 and $70 respectively. As a result, HEPA is trading at a discount of -10837.5% off the target high and -10837.5% off the low.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 63.67%.

HEPA Dividends

Hepion Pharmaceuticals Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Hepion Pharmaceuticals Inc (NASDAQ:HEPA)’s Major holders

Hepion Pharmaceuticals Inc insiders own 0.08% of total outstanding shares while institutional holders control 7.85%, with the float percentage being 7.85%.